)
)
Combigene Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Combigene
Access all reports
CombiGene AB is a biotechnology company based in Sweden, focusing on developing gene therapies for severe neurological and psychiatric disorders. The company's primary projects include treatments for drug-resistant focal epilepsy and severe chronic pain. CombiGene utilizes gene therapy vectors, specifically adeno-associated virus (AAV) vectors, to deliver therapeutic genes. The company operates in collaboration with external research entities and contract research organizations to develop its therapeutic candidates from preclinical stages to proof of concept, aiming for subsequent commercialization through strategic partnerships. The company is headquartered in Lidingö, Sweden, and its shares are listed on the Nasdaq Stockholm.
Latest articles
)
Texas Instruments: From Calculators to Master Capital Allocators
Texas Instruments has undergone many transformations from its origins in oil exploration to become one of the world's largest semiconductor producers.
11 Oct 2024
)
The Art of Portfolio Management: Lessons from Tom O'Hara
Tom O'Hara shares insights on stock picking, navigating market distractions, and the importance of one-on-one meetings with management teams.
4 Oct 2024
)
The Samsung Co-CEOs: Jong-Hee Han & Young-Hyun Jun
Samsung Electronics' dual-CEO structure, led by Jong-Hee Han and Young-Hyun Jun, is designed to navigate the complexities of its diverse business.
3 Oct 2024
Ticker symbol
COMBI
Country
🇸🇪 Sweden